TSX:FRX • CA31447P1009
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FENNEC PHARMACEUTICALS INC (FRX.CA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-23 | Cantor Fitzgerald Securities | Upgrade | Overweight |
| 2021-06-03 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-21 | Craig-Hallum | Initiate | Buy |
| 2021-04-19 | Maxim Group | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.54M | 21.252M 1,280.00% | 47.538M 123.69% | 45.957M -3.33% | 78.485M 70.78% | 98.155M 25.06% | 137.13M 39.71% | 199.52M 45.50% | 217.38M 8.95% | 197.72M -9.04% | 200.55M 1.43% | 151.86M -24.28% | |
| EBITDA YoY % growth | N/A | N/A | N/A 216.67% | 2.193M -69.29% | 30.447M 1,288.37% | 46.308M 52.09% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.59M -31.18% | -12.771M 43.47% | 2.568M 120.11% | -1.86M -172.45% | 22.134M 1,289.69% | 35.625M 60.95% | 61.455M 72.51% | 112.85M 83.63% | 120.25M 6.56% | 116.7M -2.95% | 123.47M 5.80% | 81.539M -33.96% | |
| Operating Margin | -1,466.88% | -60.09% | 5.40% | -4.05% | 28.20% | 36.29% | 44.82% | 56.56% | 55.32% | 59.02% | 61.57% | 53.69% | |
| EPS YoY % growth | -0.90 -34.33% | -0.61 32.22% | 0.00 100.00% | -0.13 -238,870,924,235,731,000.00% | 0.67 608.79% | 1.13 67.06% | 3.14 178.73% | 2.83 -9.96% | 2.85 0.84% | 2.26 -20.80% | 2.07 -8.58% | 0.90 -56.30% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.04 159.50% | 0.10 355.00% | 0.17 250.22% | 0.14 783.40% | 0.21 478.57% | 0.15 50.00% | 0.20 23.46% | 0.24 79.10% | 0.56 171.60% |
| Revenue Q2Q % growth | 14.273M 80.10% | 17.571M 100.79% | 19.449M 101.50% | 19.063M 52.97% | 21.612M 51.42% | 18.951M 7.85% | 19.981M 2.74% | 21.379M 12.15% | 27.407M 26.81% |
| EBITDA Q2Q % growth | 4.488M 780.00% | 13.566M 1,123.08% | 5.814M 533.33% | 7.854M 220.83% | 14.586M 225.00% | 7.752M -42.86% | 9.384M 61.40% | 10.812M 37.66% | 21.93M 50.35% |
| EBIT Q2Q % growth | 1.788M 291.43% | 5.21M 744.80% | 3.353M 222.73% | 5.009M 2,750.26% | 8.093M 352.63% | 5.61M 7.68% | 7.242M 115.99% | 8.772M 75.12% | 19.89M 145.77% |
All data in USD
13 analysts have analysed FRX.CA and the average price target is 21.4 CAD. This implies a price increase of 99.71% is expected in the next year compared to the current price of 10.715.
FENNEC PHARMACEUTICALS INC (FRX.CA) will report earnings on 2026-04-01, after the market close.
The consensus EPS estimate for the next earnings of FENNEC PHARMACEUTICALS INC (FRX.CA) is 0.04 CAD and the consensus revenue estimate is 14.27M CAD.
The consensus rating for FENNEC PHARMACEUTICALS INC (FRX.CA) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.